InvestorsHub Logo

DewDiligence

07/02/12 12:37 PM

#144904 RE: DewDiligence #144871

Linde acquires LNCR for $41.50/sh, a 22% premium:

http://finance.yahoo.com/news/linde-acquire-lincare-holdings-inc-120000930.html

The nominal deal value is $4.6B.

APD, a major competitor of Linde, sold to Linde its European home-healthcare segment, which is similar to LNCR, for about $800M in early 2012 (http://www.airproducts.com/company/news-center/2012/0109-air-products-to-divest-homecare-business-in-continental-europe-to-the-linde-group.aspx ). Evidently, Linde thinks packaged gases for home healthcare is a better business than its competitors do.

DewDiligence

07/02/12 3:01 PM

#144921 RE: DewDiligence #144871

BMRN, AFFY, THRX, and RIGL are the most likely candidates for the next significant biotech buyout, according to Piper Jaffray:

http://finance.yahoo.com/news/piper-discusses-potential-takeout-candidates-112833520.html

Putting THRX on the list was made easier by today’s news in #msg-77146713.

DewDiligence

07/16/12 9:35 AM

#145522 RE: DewDiligence #144871

Recent Biotech Buyouts of Publicly Traded Companies

[Added GSK-HGSI and TPG-PRX deals.]


Acquired ‡Premium *Deal iHub
Company Buyer to Market Value Date Reference

GNLB GSK 465% $57M 10/08 #msg-33209281
MEMY Roche 319% $50M 11/08 #msg-33787598
ANDS Roche 256% $220M 10/11 #msg-68043946
SYNB PFE 240% $10M 12/10 #msg-58221573
KOSN BMY 233% $190M 5/08 #msg-29647147
MGRM LH 171% $155M 6/09 #msg-38960958
COLY PFE 167% $165M 11/07 #msg-24600805
INHX BMY 163% $2.5B 1/12 #msg-70636307
CYPB Ramius 160% $255M 12/10 #msg-57780859
NTMD Deerfld z158% z$36M 1/09 #msg-35132470
ICGN PFE 150% $56M 7/11 #msg-65365128
EYE ABT 149% $2.8B 1/09 #msg-34762429
IOMI Intercell 147% $190M 5/08 #msg-29232165
CPEX FCB Hldgs 142% $77M 3/11 #msg-61326856
BTRX Stiefel 136% $150M 6/08 #msg-30201906
ISTA Bausch&Lm 134% $500M 3/12 #msg-73708628
Tepnel GPRO 126% $132M 1/09 #msg-35221710
ADLR CBST 121% $190M 10/11 #msg-68264754
SGXP LLY 119% $64M 7/08 #msg-30547648
ENCY PFE 118% $350M 2/08 #msg-26978155
TRCA Ipsen 104% $660M 6/08 #msg-29795183
AMLN BMY 101% u$7.0B 6/12 #msg-77122453
HGSI GSK 99% $3.0B 7/12 #msg-77532608
CRY.to MDT 97% $380M 9/08 #msg-32421462
Speedel NVS 94% $880M 7/08 #msg-30588524
MNT JNJ 92% $1.1B 11/08 #msg-33879830
MEDX BMY 90% $2.1B 7/09 #msg-39801273
VRUS GILD 89% $11B 11/11 #msg-69211700
SIRT GSK 85% $620M 4/08 #msg-28705020
ZGEN BMY 84% $885M 9/10 #msg-54152162
ORIDN.SW COV 77% $300M 4/12 #msg-74079493
CVTX GILD 76% $1.4B 3/09 #msg-36225695
MOVET.BR Shire 74% $560M 8/10 #msg-52918245
IDEV ENDP 74% $370M 1/09 #msg-34592416
LEVP VPHM y73% y$510M 7/08 #msg-30704409
TARG MDCO 72% $42M 1/09 #msg-34774402
Ventana Roche 72% $3.4B 1/08 #msg-30912677
Jerini Shire 71% $520M 7/08 #msg-30452872
APNO Cell Bio 70% $20M 9/09 #msg-43348606
AAH.AX CEPH 69% $207M 2/09 #msg-35956544
DDS.TO PLB.TO 68% $15M 8/11 #msg-66272770
OSTE MDT 65% $123M 8/10 #msg-53410183
TLCR Grifols 64% $3.4B 6/10 #msg-50961841
FACT ABT 64% $450M 3/10 #msg-47606240
Acambis SNY 64% $550M 7/08 #msg-30990498
JAV HSP 64% $141M 4/10 #msg-48881292
Synthes JNJ 61% $21.5B 4/11 #msg-62473819
SCRX Shionogi 61% $1.4B 9/08 #msg-31859174
BFRM Merz 60% $253M 1/10 #msg-45071380
CXS.AX CEPH 59% $163M 3/11 #msg-61453144
CRXL JNJ 58% $2.4B 12/10 #msg-57504349
MTXX HIG Captl 56% $75M 12/10 #msg-57778844
ASPM COV 56% $210M 9/09 #msg-43348479
OSIP Astellas 55% $4.0B 5/10 #msg-50234451
IDMI Takeda 55% $75M 5/09 #msg-37898204
RDEA AZN 54% $1.3B 4/12 #msg-74706626
BSMD MMSI 54% $96M 5/10 #msg-50161877
ATSI MDT 54% $370M 4/10 #msg-49617936
ALO KG 54% $1.6B 11/08 #msg-33763449
MEDI AZN 53% $15.2B 4/07 #msg-19020387
MLNM Takeda 53% $8.8B 4/08 #msg-28365383
TRBN EBS 52% $97M 8/10 #msg-53271836
SYNO BAX 52% $260M 12/11 #msg-69906294
PCOP LGND 52% $75M 9/08 #msg-32404474
CLZR ELOS 51% $65M 9/09 #msg-41293512
OMRI JNJ 51% $465M 11/08 #msg-33762745
IMCL LLY 51% $6.5B 10/08 #msg-32662830
MYOG GILD 50% $2.5B 10/06 #msg-13712121
MIL Merck KGaA 50% $7.2B 3/10 #msg-47249493
CRGN CLDX 50% $40M 5/09 #msg-38262967
BEC Danaher 46% $6.8B 2/11 #msg-59624646
PHRM CELG 46% $2.9B 11/07 #msg-24645394
CALP PKI 42% $600M 9/11 #msg-66915400
BRL TEVA 42% $9.0B 7/08 #msg-30792830
VITA SYK 41% $320M 5/11 #msg-63178312
AGAM STJ 41% $1.3B 10/10 #msg-55673504
KG PFE 40% $3.6B 10/10 #msg-55425514
CEPH TEVA 39% $6.8B 5/11 #msg-62636692
ORCH LH 39% $85M 4/11 #msg-61801828
MOGN Eisai 39% $3.9B 12/07 #msg-25163775
PRX TPG (prvt) 37% $1.9B 7/12 #msg-77533202
MTOX LH 37% $240M 6/12 #msg-76240732
GENZ SNY v37% v$20.1B 2/11 #msg-59975091
MATK Royal DSM 35% $1.1B 12/10 #msg-57987049
AMMD ENDP 34% $2.9B 4/11 #msg-61948007
CLRT GE 34% $580M 10/10 #msg-55864640
SGP MRK 34% $41B 3/09 #msg-36140327
HTRN ENDP 34% $223M 5/10 #msg-49838813
KNSY Royal DSM 33% $360M 5/12 #msg-75204020
MITI AMGN 33% $1.16B 1/12 #msg-71341339
SMTS COV 32% $250M 6/10 #msg-51344183
TOMO ARAY 31% $277M 3/11 #msg-60697854
PPDI CarlyleGrp 30% $3.9B 10/11 #msg-67625255
CGPI Galderma 30% $420M 2/08 #msg-28286522
WYE PFE 29% $68B 1/09 #msg-35077617
APPX Fresenius 29% $940M 7/08 #msg-30498388
CRA DGX 28% $330M 3/11 #msg-61103240
SEPR Dainippon 28% $2.6B 9/09 #msg-41143301
ALTH SPPI 27% $108M 4/12 #msg-74081029
GXDX NVS 27% $330M 1/11 #msg-59092015
ISPH MRK 26% $430M 4/11 #msg-61724403
Zentiva SNY 26% $2.6B 9/08 #msg-32327005
ZOLL AsahiKasei 24% $2.2B 3/12 #msg-73194976
NOVN Hisamitsu 22% $428M 7/09 #msg-39515681
DNEX TMO 21% $2.1B 12/10 #msg-57686719
GPRO HOLX 20% $3.7B 4/12 #msg-74999864
CLDA FRX 19% $1.2B 2/11 #msg-60171753
PPCO ENDP 19% $168M 8/10 #msg-53137069
EVVV COV 19% $2.6B 6/10 #msg-50797343
KCI Apax Prts 17% $6.3B 7/11 #msg-65162696
ABII CELG 17% $2.9B 6/10 #msg-51844360
ACL NVS x17% x$49.7B 1/10 #msg-45072999
PRXN.L Upshr-Smth 16% $350M 6/12 #msg-76556065
CGRB JNJ 16% $970M 5/09 #msg-38039851
DNA Roche 16% w$46.8B 3/09 #msg-36224175
ARI.to Roche 15% $190M 7/08 #msg-30904056
SENO BCR 14% $213M 5/10 #msg-49838776
EURX Axcan 9% $583M 12/10 #msg-57543845
CEGE BPAX 6% $38M 6/09 #msg-39163410
MEND JNJ 6% $480M 7/10 #msg-52176337
VXGN OXGN (4%) $33M 10/09 #msg-42578130
AVGN MNOV (7%) $38M 8/09 #msg-40769841
VRX BVF (7%) $3.9B 6/10 #msg-51505172
TRMS Synageva ® ® 6/11 #msg-64249161
PGLA Avexa ® ® 12/08 #msg-34341452
NUVO ARCA ® ® 9/08 #msg-32420015
NOVC TSPT ® ® 9/08 #msg-31869987
VSGN IPC ® ® 8/09 #msg-40603745

* Adjusted for cash/debt on acquired company’s balance sheet.

‡ Relative to “unaffected” share price in cases where
a buyout offer or auction was made public; excludes
contingent values unless otherwise specified.

® Reverse merger with private or non-US company.

u Includes $1.7B assumption of debt; premium relative to
3/27/12 close, when Bloomberg reported BMY bid. AZN pays
BMY $3.4B to put AMLN’s portfolio into 50/50 JV.

v Excluding CVR of $4-14/sh; premium relative to 7/22/10 close.

w For 44% of DNA not already owned.

x Price includes entire deal in three stages; 17% premium is the
blended avg price of NVS’ purchases ($164) relative to ACL’s market
price 4/4/08 immediately prior to announcement of first stage of deal.

y Includes $0.45/sh of contingent payments.

z Liquidated by Deerfield following failed merger with Archemix.